FOLH1 and prostate carcinoma: Initially identified as a target for the monoclonalantibody 7E11-C5.3 in prostate cancer cell lines, PSMA has since become an established target for both imaging(staging and therapy response evaluation) and radionuclide therapyin prostate cancer.